
News|Articles|December 19, 2025
2025 Brings Real-World Use of Clinical Biomarkers in Updated Multiple Sclerosis Diagnostic Criteria
Author(s)Isabella Ciccone, MPH
Fact checked by: Patrick Campbell
Discover how updated diagnostic criteria for multiple sclerosis enhance accuracy and confidence in clinical practice, utilizing advanced imaging and biomarkers.
Advertisement
Advertisement
The latest diagnostic criteria for multiple sclerosis (MS) were initially presented at the
Related to this article

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Advertisement
Advertisement

